Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$12000.0.

  • Lineage Cell Therapeutics' Cash from Investing Activities fell 10030.86% to -$12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 598.04%. This contributed to the annual value of -$2.3 million for FY2024, which is 10496.89% down from last year.
  • Lineage Cell Therapeutics' Cash from Investing Activities amounted to -$12000.0 in Q3 2025, which was down 10030.86% from -$14000.0 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Cash from Investing Activities high stood at $19.2 million for Q2 2023, and its period low was -$40.9 million during Q3 2022.
  • In the last 5 years, Lineage Cell Therapeutics' Cash from Investing Activities had a median value of -$14000.0 in 2025 and averaged $505473.7.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Cash from Investing Activities tumbled by 6006764.71% in 2022 and then soared by 3363478.26% in 2023.
  • Lineage Cell Therapeutics' Cash from Investing Activities (Quarter) stood at -$146000.0 in 2021, then crashed by 3394.52% to -$5.1 million in 2022, then soared by 290.94% to $9.7 million in 2023, then plummeted by 72.95% to $2.6 million in 2024, then plummeted by 100.46% to -$12000.0 in 2025.
  • Its Cash from Investing Activities was -$12000.0 in Q3 2025, compared to -$14000.0 in Q2 2025 and $1.9 million in Q1 2025.